Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages.

Berger E, Breznan D, Stals S, Jasinghe VJ, Gonçalves D, Girard D, Faucher S, Vincent R, Thierry AR, Lavigne C.

Nanobiomedicine (Rij). 2017 Dec 21;4:1849543517746259. doi: 10.1177/1849543517746259. eCollection 2017 Jan-Dec.

2.

A Step Closer to Cancer Screening by Blood Test.

Thierry AR.

Clin Chem. 2018 Jun 14. pii: clinchem.2018.287847. doi: 10.1373/clinchem.2018.287847. [Epub ahead of print] No abstract available.

PMID:
29903875
3.

Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer.

Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, El Messaoudi S, Otandault A, Canterel-Thouennon L, Busson M, Thierry AR, Martineau P, Pannequin J, Roche S, Sirvent A.

EMBO Mol Med. 2018 Apr;10(4). pii: e7918. doi: 10.15252/emmm.201707918.

4.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M.

Ann Oncol. 2017 Sep 1;28(9):2149-2159. doi: 10.1093/annonc/mdx330.

PMID:
28911069
5.

Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S.

Clin Cancer Res. 2017 Aug 15;23(16):4578-4591. doi: 10.1158/1078-0432.CCR-17-0232. Epub 2017 Apr 11.

PMID:
28400427
6.

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.

Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.

PMID:
28280091
7.

Origins, structures, and functions of circulating DNA in oncology.

Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M.

Cancer Metastasis Rev. 2016 Sep;35(3):347-76. doi: 10.1007/s10555-016-9629-x. Review.

8.

Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR.

Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.

9.

A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.

Thierry AR.

Methods Mol Biol. 2016;1392:1-16. doi: 10.1007/978-1-4939-3360-0_1.

PMID:
26843041
10.

DNA studies using atomic force microscopy: capabilities for measurement of short DNA fragments.

Pang D, Thierry AR, Dritschilo A.

Front Mol Biosci. 2015 Jan 29;2:1. doi: 10.3389/fmolb.2015.00001. eCollection 2015. Review.

11.

Non-invasive pre-implantation genetic diagnosis of X-linked disorders.

Assou S, Aït-Ahmed O, El Messaoudi S, Thierry AR, Hamamah S.

Med Hypotheses. 2014 Oct;83(4):506-8. doi: 10.1016/j.mehy.2014.08.019. Epub 2014 Aug 23.

PMID:
25182520
12.

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR.

Mol Oncol. 2014 Jul;8(5):927-41. doi: 10.1016/j.molonc.2014.02.005. Epub 2014 Mar 24.

13.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.

Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M.

Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.

PMID:
24658074
14.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, Molina F, Lamy PJ, Lopez-Crapez E, Mathonnet M, Ychou M, Pezet D, Thierry AR.

Transl Oncol. 2013 Jun 1;6(3):319-28. Print 2013 Jun.

15.

Circulating cell free DNA: Preanalytical considerations.

El Messaoudi S, Rolet F, Mouliere F, Thierry AR.

Clin Chim Acta. 2013 Sep 23;424:222-30. doi: 10.1016/j.cca.2013.05.022. Epub 2013 May 30. Review.

PMID:
23727028
16.

Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor.

Lavigne C, Slater K, Gajanayaka N, Duguay C, Arnau Peyrotte E, Fortier G, Simard M, Kell AJ, Barnes ML, Thierry AR.

Expert Opin Biol Ther. 2013 Jul;13(7):973-85. doi: 10.1517/14712598.2013.743526. Epub 2013 Jan 7.

PMID:
23289797
17.

The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients.

Mouliere F, Thierry AR.

Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S209-15. doi: 10.1517/14712598.2012.688023. Epub 2012 May 18. Review.

PMID:
22594497
18.

High fragmentation characterizes tumour-derived circulating DNA.

Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, Gongora C, Thierry AR.

PLoS One. 2011;6(9):e23418. doi: 10.1371/journal.pone.0023418. Epub 2011 Sep 6.

19.

Computing with bacterial constituents, cells and populations: from bioputing to bactoputing.

Norris V, Zemirline A, Amar P, Audinot JN, Ballet P, Ben-Jacob E, Bernot G, Beslon G, Cabin A, Fanchon E, Giavitto JL, Glade N, Greussay P, Grondin Y, Foster JA, Hutzler G, Jost J, Kepes F, Michel O, Molina F, Signorini J, Stano P, Thierry AR.

Theory Biosci. 2011 Sep;130(3):211-28. doi: 10.1007/s12064-010-0118-4. Epub 2011 Mar 8. Review.

20.

BioNetCAD: design, simulation and experimental validation of synthetic biochemical networks.

Rialle S, Felicori L, Dias-Lopes C, Pérès S, El Atia S, Thierry AR, Amar P, Molina F.

Bioinformatics. 2010 Sep 15;26(18):2298-304. doi: 10.1093/bioinformatics/btq409. Epub 2010 Jul 13.

21.

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F.

Nucleic Acids Res. 2010 Oct;38(18):6159-75. doi: 10.1093/nar/gkq421. Epub 2010 May 21.

22.

Cryotreatment as a simple method for cell preparation in autologous tumor cell-based vaccination.

Maltais M, Thierry AR, Walshaw SO, Lavigne C.

Int J Oncol. 2010 Mar;36(3):617-22.

PMID:
20126982
23.

Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy.

Resina S, Prevot P, Thierry AR.

PLoS One. 2009 Jun 26;4(6):e6058. doi: 10.1371/journal.pone.0006058.

24.

Lipoplex nanostructures reveal a general self-organization of nucleic acids.

Thierry AR, Norris V, Molina F, Schmutz M.

Biochim Biophys Acta. 2009 May;1790(5):385-94. doi: 10.1016/j.bbagen.2009.03.017. Epub 2009 Apr 1.

PMID:
19344746
25.

A rapid microwell fluorescence immunoassay for cellular protein detection.

Lavigne C, Guignée de A, Thierry AR.

Biol Proced Online. 2008 Sep 22;10:83-9. doi: 10.1251/bpo146.

26.

Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells.

Lavigne C, Thierry AR.

Biochimie. 2007 Oct;89(10):1245-51. Epub 2007 May 17.

PMID:
17619075
27.

Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides.

Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, Gait MJ, Thierry AR, Lebleu B.

Int J Pharm. 2007 Nov 1;344(1-2):96-102. Epub 2007 May 17.

PMID:
17600642
28.

Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range.

Meryet-Figuières M, Resina S, Lavigne C, Barlovatz-Meimon G, Lebleu B, Thierry AR.

Biochimie. 2007 Oct;89(10):1228-33. Epub 2007 Apr 2.

PMID:
17509745
29.

Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides.

Resina S, Kole R, Travo A, Lebleu B, Thierry AR.

J Gene Med. 2007 Jun;9(6):498-510.

PMID:
17471591
30.

Comparison of basic peptides- and lipid-based strategies for the delivery of splice correcting oligonucleotides.

Thierry AR, Abes S, Resina S, Travo A, Richard JP, Prevot P, Lebleu B.

Biochim Biophys Acta. 2006 Mar;1758(3):364-74. Epub 2005 Nov 18. Review.

31.

Toward high yield synthesis of peptide-oligonucleotide chimera through a disulfide bridge: a simplified method for oligonucleotide activation.

Maurel F, Debart F, Cavelier F, Thierry AR, Lebleu B, Vasseur JJ, Vivès E.

Bioorg Med Chem Lett. 2005 Nov 15;15(22):5084-7.

PMID:
16168651
32.
33.

Cellular uptake and intracellular fate of antisense oligonucleotides.

Thierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B.

Curr Opin Mol Ther. 2003 Apr;5(2):133-8. Review.

PMID:
12772502
34.
35.

Characterization of a synthetic anionic vector for oligonucleotide delivery using in vivo whole body dynamic imaging.

Tavitian B, Marzabal S, Boutet V, Kühnast B, Terrazzino S, Moynier M, Dollé F, Deverre JR, Thierry AR.

Pharm Res. 2002 Apr;19(4):367-76.

PMID:
12033366
36.

DNA packing in stable lipid complexes designed for gene transfer imitates DNA compaction in bacteriophage.

Schmutz M, Durand D, Debin A, Palvadeau Y, Etienne A, Thierry AR.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12293-8.

37.

Radiotoxicity of iodine-125-labeled oligodeoxyribonucleotides in mammalian cells.

Sedelnikova OA, Panyutin IG, Thierry AR, Neumann RD.

J Nucl Med. 1998 Aug;39(8):1412-8.

38.

Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system.

Lavigne C, Thierry AR.

Biochem Biophys Res Commun. 1997 Aug 28;237(3):566-71.

PMID:
9299405
39.

Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme).

Takle GB, Thierry AR, Flynn SM, Peng B, White L, Devonish W, Galbraith RA, Goldberg AR, George ST.

Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):177-85.

PMID:
9212908
40.

Nomenclature for synthetic gene delivery systems.

Felgner PL, Barenholz Y, Behr JP, Cheng SH, Cullis P, Huang L, Jessee JA, Seymour L, Szoka F, Thierry AR, Wagner E, Wu G.

Hum Gene Ther. 1997 Mar 20;8(5):511-2. No abstract available.

PMID:
9095402
41.

Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA.

Thierry AR, Rabinovich P, Peng B, Mahan LC, Bryant JL, Gallo RC.

Gene Ther. 1997 Mar;4(3):226-37.

42.

Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes.

Baudard M, Flotte TR, Aran JM, Thierry AR, Pastan I, Pang MG, Kearns WG, Gottesman MM.

Hum Gene Ther. 1996 Jul 10;7(11):1309-22.

PMID:
8818718
43.

In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells.

Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR.

Hum Gene Ther. 1996 Jun 10;7(9):1111-22.

PMID:
8773513
44.

Systemic gene therapy: biodistribution and long-term expression of a transgene in mice.

Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9742-6.

45.

Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone.

Lunardi-Iskandar Y, Bryant JL, Zeman RA, Lam VH, Samaniego F, Besnier JM, Hermans P, Thierry AR, Gill P, Gallo RC.

Nature. 1995 May 4;375(6526):64-8. Erratum in: Nature 1995 Aug 3;376(6539):447.

PMID:
7723844
46.

Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.

Lisziewicz J, Sun D, Weichold FF, Thierry AR, Lusso P, Tang J, Gallo RC, Agrawal S.

Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7942-6.

47.

A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumor cells.

Thierry AR, Rahman A, Dritschilo A.

Cancer Chemother Pharmacol. 1994;35(1):84-8.

PMID:
7987982
48.

Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.

Thierry AR, Vigé D, Coughlin SS, Belli JA, Dritschilo A, Rahman A.

FASEB J. 1993 Apr 1;7(6):572-9.

PMID:
8097173
49.

Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides.

Thierry AR, Rahman A, Dritschilo A.

Biochem Biophys Res Commun. 1993 Feb 15;190(3):952-60.

PMID:
8094959
50.

Progress in antisense research and development.

Thierry AR, Bradley MO, Chrisey LA.

Antisense Res Dev. 1993 Winter;3(4):411-6. No abstract available.

PMID:
8155983

Supplemental Content

Loading ...
Support Center